Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. assumed coverage on Zai Lab in a research report on Monday, October 16th. They set a “neutral” rating and a $32.00 target price for the company. Citigroup assumed coverage on Zai Lab in a research report on Monday, October 16th. They set a “buy” rating for the company. Finally, Leerink Swann assumed coverage on Zai Lab in a research report on Monday, October 16th. They set an “outperform” rating and a $42.00 target price for the company.

Shares of Zai Lab (NASDAQ:ZLAB) opened at $23.63 on Wednesday. The company has a market capitalization of $1,130.00 and a PE ratio of -23.17. Zai Lab has a 12-month low of $20.67 and a 12-month high of $35.74.

An institutional investor recently bought a new position in Zai Lab stock. FNY Partners Fund LP bought a new position in shares of Zai Lab Ltd (NASDAQ:ZLAB) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 5,100 shares of the company’s stock, valued at approximately $137,000. Institutional investors own 18.24% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zai Lab (ZLAB) Rating Increased to Sell at BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.watchlistnews.com/zai-lab-zlab-rating-increased-to-sell-at-bidaskclub/1801136.html.

Zai Lab Company Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.